Clinical Trial Results: A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase III non-inferiority trial comparing subcutaneous versus intravenous ocrelizumab in relapsing and primary progressive multiple sclerosis; results completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis
• Relapsing Multiple Sclerosis

Drugs mentioned

• Ocrelizumab (ocrelizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2026-08-11